SOURCE: Basilea Pharmaceutica AG

September 16, 2010 02:05 ET

New data on three compounds from Basilea's anti-infectives portfolio presented at ICAAC

BASEL, SWITZERLAND--(Marketwire - September 16, 2010) -

Basilea Pharmaceutica AG / New data on three compounds from Basilea's anti- infectives portfolio presented at ICAAC processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, September 16, 2010 - Data on the novel antibiotic compound BAL30072, on ceftobiprole and isavuconazole were presented at the 50(th) annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston. The data on BAL30072 specifically demonstrate the high in-vitro activity of the new monosulfactam antibiotic against multi-resistant Gram-negative bacteria and elucidate structural elements involved in its unique antimicrobial activity.

Multi-resistant Gram-negative bacteria are appearing with increasing frequency in hospitals around the world causing an increase in mortality, particularly when initial antibiotic therapy does not provide coverage of the causative pathogen, and putting a significant economic burden on healthcare systems. The local emergence of new antibiotic resistance mechanisms against almost all available therapeutics will spread to a worldwide public health problem unless new antibiotics active against multi-resistant bacteria are developed.

BAL30072 - a Trojan horse fighting resistance of Gram-negative bacteria

BAL30072 is a novel siderophore monosulfactam antibiotic that can act like a "Trojan horse" by exploiting natural nutrient uptake systems to gain access to its target. New in-vitro data reveal that a specific structural element of the BAL30072 molecule, the siderophore side chain, contributes directly to its antibacterial activity against clinically increasingly problematic multi-resistant Gram-negative bacteria such as Pseudomonas spp. and Klebsiella spp. (Poster F1-2132). Furthermore, there is new evidence that an accelerated uptake of BAL30072, facilitated by the compound's siderophore side chain, potentiates its in-vitro activity against Acinetobacter baumannii, a pathogen which can cause severe pneumonia and infections of the urinary tract and bloodstream (Poster F1-2133).

Basilea is preparing for moving BAL30072 into phase I clinical testing in Q4 2010.

+-----------------------------------------------------------------------+
|Posters on BAL30072 at ICAAC 2010                                      |
|                                                                       |
|The Role of the Siderophore Moiety in the Activity of the Novel        |
|Monosulfactam                                                          |
|BAL30072. - M. G. P. PAGE, F. RICHALET, C. MÜLLER, B. HOFER, E.
|
|DESARBRE; F1-2132                                                      |
|F1-2132                                                                |
|                                                                       |
|Enhanced Activity of the Siderophore Monosulfactam BAL30072 (BAL)      |
|against                                                                |
|Acinetobacter in Iron-Limited Conditions. - M. G. PAGE, C. MÜLLER,
|
|B. HOFER,                                                              |
|                                                                       |
|                                                                       |
|Exploring Novel Inhibitors of FOX-4 Class C --Lactamase. - S. MALLO, C.|
|BETHEL, F. PEREZ-LLARENA, F. PRATI, E. CASELLI, M. PAGE, G. BOU, R.    |
|E. DESARBRE; F1-2133  BONOMO;                                          |
|F1-2134                                                                |
|                                                                       |
|CMY-33, A Novel Extended Spectrum Beta-Lactamase (ESBL) of the CMY-2   |
|Family. -                                                              |
|M. TARACILA, A. ENDIMIANI, C. R. BETHEL, Y. DOI, M. G. P. PAGE, R. A.  |
|BONOMO; C1-1961                                                        |
|                                                                       |
|                                                                       |
|For further information please visit www.icaac.org                     |
+-----------------------------------------------------------------------+


Ceftobiprole and isavuconazole - broad-spectrum antimicrobial activity for the treatment of potentially life-threatening infections

A series of posters further adds to the wealth of existing in-vitro and clinical data underscoring the broad-spectrum activity of the antibiotic ceftobiprole against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and Gram-negative pathogens, including Pseudomonas spp. In particular, ceftobiprole demonstrates bactericidal in-vitro activity against clinical isolates of Enterococcus faecalis, unlike other cephalosporins (Poster A1-1376). Enterococci belong to the most common pathogens involved in hospital-associated infections and frequently cause bloodstream infections and wound infections in hospitalized patients. Furthermore, Kim and co-workers unveil in abstract E-2043 in-vitro results from the Asian Network for Surveillance of Resistant Pathogens (ANSORP) study comprising major respiratory isolates from hospital-acquired pneumonia (HAP) from 10 Asian countries. The authors conclude that ceftobiprole could be an important therapeutic option for HAP caused by resistant pathogens.

Isavuconazole, a novel broad-spectrum triazole in phase III clinical testing against potentially life-threatening invasive fungal infections, showed potent in-vitro activity against a large panel of recent clinical isolates of Aspergillus spp. (Poster M-375).

+-----------------------------------------------------------------------+
|Posters on ceftobiprole at ICAAC 2010                                  |
|                                                                       |
|Pharmacodynamic (PD) Activity of Ceftobiprole (Cefto) Compared to      |
|Vancomycin                                                             |
|(Vanco) vs. Enterococcus faecalis Using an In Vitro Model. - G. G.     |
|ZHANEL, N.                                                             |
|LAING, L. COX, E. ROSSNAGEL, D. VOTH, J. A. KARLOWSKY, D. J. HOBAN;    |
|A1-1376                                                                |
|                                                                       |
|Efficacy of Ceftobiprole (BPR) Alone and in Combination with Vancomycin|
| (VAN)                                                                 |
|in a Rat MRSA Infective Endocarditis (IE) Model. - J. FERNANDEZ, D.    |
| ABBANAT,                                                              |
|R. K. FLAMM, J. HASTINGS, A. M. BARRON, A. S. LYNCH; B-061             |
|                                                                       |
|In Vivo Synergism of Ceftobiprole in Combination with Vancomycin       |
|against                                                                |
|Experimental Endocarditis Due to Vancomycin-Intermediate Staphylococcus|
|aureus. - J. VOUILLAMOZ, J. M. ENTENZA, T. R. VELOSO, M. GIDDEY, P.    |
|MOREILLON;                                                             |
|B-062                                                                  |
|                                                                       |
|Characterization of --Lactamase Negative Ampicillin-Resistant (BLNAR)  |
|and                                                                    |
|--Lactamase Positive Amoxicillin-Clavulanate-Resistant (BLPACR)        |
|Haemophilus                                                            |
|influenzae. - T. A. DAVIES, A. E. STEVENSON, W. HE, G. J. NOEL, S. I.  |
| PELTON;                                                               |
|C2-117                                                                 |
|                                                                       |
|In Vitro Activities of Ceftaroline and Ceftobiprole against Penicillin-|
|and                                                                    |
|Macrolide-Non-Susceptible Streptococcus pneumoniae (SPN)-CANWARD 2009. |
| - A. K.                                                               |
|WIERZBOWSKI1, H. J. ADAM, J. KARLOWSKY, D. J. HOBAN, G. G. ZHANEL;     |
|E-818                                                                  |
|                                                                       |
|Effects of Ceftobiprole and Comparators Alone and in Combination in an |
|in                                                                     |
|vitro Staphylococcal Biofilm Model. - D. ABBANAT, C. SANTORO, W. SHANG,|
| E.                                                                    |
|BAUM, S. CRESPO-CARBONE, A. S. LYNCH; E-1562                           |
|                                                                       |
|In Vitro Activities of Ceftobiprole and Doripenem against Major        |
|Bacterial                                                              |
|Isolates of Hospital-Acquired Pneumonia in Asian Countries: An ANSORP  |
Study. -                                                                |
|S. KIM, J. SONG, D. CHUNG, M. LEE, K. KO, Ansorp Study Group; E-2043   |
|                                                                       |
|Poster on isavuconazole at ICAAC 2010                                  |
|                                                                       |
|Isavuconazole Wild-Type (WT) MIC Distributions and Epidemiological     |
|Cut-Off                                                                |
|Values (ECVs) for Clinical Isolates of Aspergillus spp. - T. PELÁEZ    |
|A.                                                                     |
|ESPINEL-INGROFF, B. GAMA, E. REIGADAS, J. GUINEA, L. ALCALÁ, P.        |
| MUÑOZ, E.                                                             |
|BOUZA; M-375                                                           |
|                                                                       |
|For further information please visit www.icaac.org                     |
+-----------------------------------------------------------------------+

About Basilea


Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SWISS: BSLN). Its fully integrated research and development operations are currently focused on antibiotics, antifungals and oncology drugs, as well as on the development of dermatology drugs, targeting the medical challenge of resistance and non-response to current treatment options in the hospital and specialty care setting.

Basilea is currently marketing Toctino® (alitretinoin), the only approved treatment for severe chronic hand eczema unresponsive to potent topical corticosteroids, in Denmark, France, Germany, Switzerland and the United Kingdom and has appointed distributors for Toctino® in other selected European markets, Canada and Mexico. Furthermore, a phase III clinical program on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. The company has entered into a global partnership with Astellas Pharma Inc. for its phase III compound isavuconazole, a potential best-in-class azole antifungal, for the treatment of life-threatening invasive fungal infections. Full rights to ceftobiprole for the treatment of potentially life-threatening resistant bacterial infections are being transferred back to Basilea from Cilag GmbH International, a Johnson & Johnson company.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

+-----------------------------+--------------------------------+
| Media Relations             | Investor Relations             |
+-----------------------------+--------------------------------+
| Adesh Kaul                  | Barbara Zink, Ph.D., MBA       |
| Head Public Relations &     | Head Corporate Development     |
| Corporate Communications    |                                |
| +41 61 606 1460             | +41 61 606 1233                |
| media_relations@basilea.com | investor_relations@basilea.com |
+-----------------------------+--------------------------------+

This press release can be downloaded from www.basilea.com


[HUG#1444708]


--- End of Message ---

Basilea Pharmaceutica AG

Grenzacherstrasse 487
P.O Box Basel Switzerland


Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;


Press Release (PDF):
http://hugin.info/134390/R/1444708/388283.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

Contact Information